"After finding out half a million tests were far from enough, we had to work out how to produce five million"

Jakob Gudbrand leads US lab giant Thermo Fisher Scientific's efforts to combat the Covid-19 pandemic.

Thermo Fisher President for Pharma & Biotech Scientific Jakob Gudbrand. | Photo: GN Store Nord / PR

When Covid-19 entered the stage in the late spring of 2020, it changed everything that Jakob Gudbrand had imagined for the days to come.

Based out of Florida, and working as the president for Pharma & Biotech in the US lab giant Thermo Fisher Scientific, he has been responsible for major client relations and global strategy in pharma and biotech since January 2020 – and when the Covid-19 pandemic started wreaking havoc, he soon got a different role to play.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs